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The incidence and prevalence rates of inf lammatory bowel disease (IBD) have 
been increasing in East Asian countries over the past few decades. Accordingly, 
the general understanding and awareness of IBD among healthcare professionals 
has increased considerably in this region. This increase is ultimately associat-
ed with the evolving focus of IBD clinicians devoted to comprehensive patient 
care, especially in establishing IBD clinics/centers capable of providing multi-
disciplinary counseling. Comprehensive IBD care at IBD clinics/centers usually 
includes surgical and medication decision-making, transition from pediatric to 
adult clinics, care of extraintestinal manifestations, care of infectious diseases in 
patients undergoing immunomodulatory or biologic therapies, and nutritional, 
psychosocial, socioeconomic, and pharmacological care. Team members com-
prise specialists from various departments related to IBD and can be divided 
into core and ad hoc members. Usually, the scope of work in IBD clinics/centers 
involves patient care, patient outreach, and system management. Considering 
the environmental changes in IBD treatment, it is necessary to perform compre-
hensive IBD patient care in the form of a program based on competencies, rather 
than simply following the organization of previous IBD centers. The present 
review summarizes recent trends in IBD patient care and offers perspectives re-
garding IBD center management.
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INTRODUCTION
Inflammatory bowel diseases (IBDs), including Crohn’s 
disease (CD) and ulcerative colitis (UC), exhibit chron-
ic, recurrent, complicated, and heterogeneous clini-
cal characteristics. Although genetic, immunological, 
environmental, and microbial factors are believed to 
be associated with the development of IBD, the exact 
pathogenesis remains unclear [1,2]. Despite IBD not 
being as prevalent in East Asian compared with West-
ern countries, its incidence has been increasing during 
the past few decades in East Asia, especially in Korea, 
Taiwan, Japan, India, and China [3]. The reasons for the 
rapid increase in incidence are not clear, but changes in 
dietary habits and the environment, advances in diag-
nostic technologies, and physician awareness have been 
proposed as contributing factors [4]. Additionally, thera-
peutic approaches have been developed based on in vivo 
and in vitro investigations targeting specific cytokine 
pathways and/or adhesion molecules [5]. 
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Unfortunately, a considerable number of IBD patients 
ultimately require surgical intervention and experience 
diverse complications, including extraintestinal mani-
festations (EIMs) and complications of the disease itself, 
such as strictures, fistulas, and/or abscesses [6]. Psycho-
logical issues and socioeconomic burdens are also of-
ten associated with IBD [7]. Recently, patient quality of 
life has been recognized as an important issue in the 
treatment of IBD. Novel biologic agents introduced in 
recent decades have revolutionized IBD care by provid-
ing diverse therapeutic options [8]. These changes and 
the heterogeneity of the disease itself have prompted 
the development of personalized therapies, which can 
be administered most efficiently at IBD clinics/centers. 
Therefore, patient care for IBD involves more compre-
hensive and centralized demands than for any other dis-
ease due to the complexities of IBD and various clinical 
aspects, including new drugs, surgical interventions, 
EIMs, and nutritional and psychological issues.
The present review describes the current status of IBD 
treatment in Korea, proposes avenues to optimize and 
improve treatment strategies, and identifies important 
factors in IBD clinic/center management.
THE EPIDEMIOLOGY OF IBD IN KOREA
The incidence of a particular disease refers to the num-
ber of newly diagnosed patients in a population during 
a specific period [9]. Although several epidemiological 
studies have investigated IBD in East Asian countries, it 
is difficult to make direct comparisons among studies 
due to variation in screening criteria, diagnostic defini-
tions, target populations, and data sources. Fortunately, 
population- and big data-based studies in Korea using 
nationwide population data have been recently pub-
lished. During the 2011 to 2014 period, the average an-
nual incidences of CD and UC in Korea were 2.8 and 
5.0 per 100,000, respectively, based on national health 
insurance data [10]. Similar results have been reported 
in other studies [11]. Compared with other East Asian 
countries, the incidence and prevalence rates of IBD in 
Korea are the second highest after Japan. The overall 
crude annual incidences of CD and UC in Asia were es-
timated as 0.35 (95% confidence interval [CI], 0.31 to 0.40) 
and 0.76 (95% CI, 0.69 to 0.84) in 2011 to 2012 and 0.66 
(95% CI, 0.60 to 0.73) and 1.20 (95% CI, 1.11 to 1.29) in 
2012 to 2013, respectively [12]. The crude incidences of 
CD and UC in Taiwan specifically were 0.47 and 0.95 per 
100,000 in 2015, respectively [13]. The crude incidence 
rate of IBD in 2011 to 2012 was 3.06 (95% CI, 2.49 to 3.73) 
in Hong Kong, 3.44 (95% CI, 2.47 to 4.42) in mainland 
China (Guangzhou), and 1.06 (95% CI, 0.76 to 1.45) in 
Singapore [14]. Previously, IBD was considered a disease 
that is predominantly prevalent in Western countries; 
however, the incidence rate has increased throughout 
East Asia over the past 20 years [15]. 
Similar to the incidence rate, the prevalence rate of 
IBD has steadily increased over time due to the chronic 
nature and increasing incidence of the disease as well as 
global aging trends. Although still lower in East Asian 
compared with Western countries [15], the prevalence 
rates of CD and UC in Taiwan during the 2000s increased 
sharply from 0.6 and 2.1 per 100,000 in 2001 to 3.9 and 
12.8 per 100,000 in 2015, respectively [13]. From 2009 to 
2016, the prevalence of CD in Korea increased from 16.0 
to 29.6 per 100,000, whereas that of UC increased from 
41.4 to 66.0 per 100,000 [16], the incidence of CD in Korea 
increased from 2.4 to 2.9 per 100,000, whereas that of UC 
increased from 4.0 to 5.3 per 100,000 [16]. Research on 
local populations in Korea revealed similar results, with 
an adjusted prevalence rate of 76.66 per 100,000 for UC 
and 31.59 per 100,000 for CD in 2015 [17]. In Hong Kong, 
the adjusted prevalence rates of UC and CD were 24.5 
and 18.6 per 100,000 in 2014, respectively [18]. Consider-
ing that IBD patients represent approximately 0.9% and 
0.3% of the populations of the United States and Europe, 
respectively, the prevalence of IBD in East Asia remains 
relatively low, yet is steadily increasing. Specifically, inci-
dence trends for pediatric IBD in Korea have increased 
markedly, especially within the past 5 years, and the inci-
dence rate of perianal disease is higher in Korean than in 
Western children (43.9% vs. 9%–15%) [19]. Additionally, 
according to a nationwide registry, the number of anal 
surgeries conducted in IBD patients in Korea is large 
due to the high rate of anal involvement, and the rate of 
laparoscopic surgery increased dramatically from 11.6% 
in 2009 to 30% in 2015 [20]. Overall, it is expected that the 
number of IBD patients in Korea will increase further. 
Therefore, it is necessary to systematically construct a 
comprehensive IBD treatment environment comparable 
with that of Western countries. 
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IBD-RELATED CLINICAL TRIALS IN KOREA
The developmental environment for IBD-related clini-
cal trials in Korea is similar to that for IBD epidemiolo-
gy. A search of the website for new investigational drug 
applications (http://nedrug.mfds.go.kr) from all clinical 
trials approved by the Korean Ministry of Food and Drug 
Safety was conducted in March 2020 using the keywords 
“CD,” “UC,” “IBD,” “intestinal Behçet’s disease,” and 
combinations thereof. As shown in Fig. 1, the number of 
new IBD clinical trials has increased considerably in Korea 
[21]. From 2008 to 2019, 37 (30.6%) phase II and 64 (52.9%) 
phase III clinical trials among all IBD clinical trials were 
conducted. Conversely, relatively fewer phase I clinical tri-
als for IBD have been conducted in Korea. 
More approved clinical research trials will lead to a 
greater rate of approved medications on the market, ul-
timately providing more therapeutic options for IBD pa-
tients. Consequently, IBD patients in Korea would ben-
efit from an expanded range of new therapeutic options; 
however, the number of clinical trials is not always con-
sistent with the number of approved drugs. Collectively, 
the statuses of these clinical trials and newly approved 
medications provide evidence illustrating the increas-
ing complexity of IBD treatment. Moreover, health pro-
fessionals, especially IBD specialists, should aim to gain 
a more accurate understanding of disease mechanisms 
and their impact on therapeutic decisions to optimize 
the initiation, selection, and sequencing of biologics 
[22]. Such changes will be among the components driv-
ing the development of the IBD treatment environment 
in Korea, with more biological and small-molecule ther-
apies and advanced drug-response monitoring, includ-
ing therapeutic drug monitoring [23]. 
IBD CLINICS/CENTERS AND MULTIDISCI-
PLINARY TREATMENT 
The disease complexity, heterogeneity, and EIMs of 
IBD require a coordinated and collaborative therapeu-
tic approach involving gastroenterologists, colorectal 
surgeons, pediatric gastroenterologists, radiologists, 
IBD nurses, dieticians, and pharmacists. Thus, mul-
tidisciplinary and team-based patient care is strongly 
recommended for the optimal treatment of IBD [24,25]. 
Because clinical treatment decisions and opinions re-
garding IBD often differ among various types of clini-
cians, a multidisciplinary team approach is very import-
ant for achieving consensus and standardization of IBD 
care services. This is a prominent trend in the recent 
medical environment and has originated from the treat-
Figure 1. Number of protocols for assessing investigational drugs for inflammatory bowel disease approved annually by 
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ment of cancers and chronic diseases other than IBD 
[26,27]. Moreover, IBD care has evolved from physician 
superiority to a shared decision-making process involv-
ing patients and/or patient empowerment, which can 
lead to greater treatment adherence in patients [28]. In 
the presence of effective multidisciplinary communica-
tion, while ensuring patient safety considering the char-
acteristics of IBD, team-based approaches have gained 
popularity. Such an approach may involve the following 
components: surgery-related decisions, such as the op-
timal timing, necessity of surgery, and/or postoperative 
care; determining the appropriate timing or selection 
of medications; special care for patients experiencing 
EIMs; care for patients receiving immunomodulatory 
or biologic therapies, who are at high risk of infection; 
nutritional, psychosocial, obstetrical, pharmacological, 
and socioeconomic care; and the transition from pedi-
atric to adult clinical care. Focused services could lead 
to more appropriate clinical decisions by increasing the 
efficiency of the professionals delivering IBD services. 
All of these activities can be integrated in an IBD clinic/
center. Worldwide, the major leading hospitals are now 
operating multidisciplinary treatment programs and 
systems based on IBD clinics/centers. 
In Korea until the early 2010s, most university or 
tertiary hospitals provided multidisciplinary care cen-
tered on gastroenterologists, without establishing of-
ficial clinics/centers. Most hospitals focused on IBD 
patient treatment are now establishing and operating 
official IBD clinics/centers, which generally integrate 
staff members from various departments. Based on the 
experience of Severance Hospital (Seoul, Korea), these 
staff members can be divided into core and ad hoc mem-
bers (Table 1). Core members participate mainly in rou-
tine multidisciplinary treatment, patient outreach, and 
annual/regular IBD patient seminars. Thus, the core 
members participate in regular conferences or meetings 
to discuss routine tasks ranging from patient issues to 
clinical and administrative issues. The ad hoc members 
facilitate collaboration regarding specific patients and 
situations. For example, the care of patients transition-
ing from a pediatric clinic/center to an adult facility and 
those requiring minor procedures necessitates collab-
oration between IBD nurses, gastroenterologists, and 
pediatricians. For patients initiating biologic agents, 
infectious disease physicians and gastroenterologists 
discuss and screen for the risk of tuberculosis and any 
other infections, while IBD nurses and infusion nurs-
es work together to design infusion schedules. Accord-
ingly, most IBD clinics/centers have subdivisions. The 
most typical system involves a CD, UC, or intestinal Be-
hçet’s disease clinic within the IBD center depending on 
the focal disease entity. Alternatively, the clinics can be 
organized according to field, such as transition, fertility, 
and/or ostomy clinics. The clinic composition may vary 
depending on the characteristics of each hospital or the 
areas of focus of the participating members.
TASKS OF IBD CLINICS/CENTERS: THREE MA-
JOR CATEGORIES
Using Severance Hospital as an example, the work of an 
IBD clinic is divided into three major categories: patient 
care, patient outreach, and system management (Table 
2). Multidisciplinary conferences, as part of the patient 
Table 1. Core and ad hoc member groups at the Severance Hospital IBD Clinic (Seoul, Korea)
Core member Gastroenterologist Colorectal surgeon Pediatric 
gastroenterologist
Radiologist
IBD nurse Dietician Pharmacist Social service worker
Ad hoc member Dermatologista Psychiatrist Rheumatologista
Histopathologistb Infectious disease physicianc Obstetrician
Wound, ostomy, continence nurseb Clinical research coordinator Infusion nursec
IBD, inflammatory bowel disease.
aTreatment for intestinal Behçet’s disease. 
bIn case of surgery. 
cIn case of biologics initiation.
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care category, can be conducted by core and ad hoc mem-
bers, whereas patient participation is not always neces-
sary. When deciding whether to perform surgery, a con-
ference between the patients, colorectal surgeon, and 
gastroenterologist is most effective. Conversely, when 
considering a differential diagnosis or designing a ther-
apeutic strategy, it may be more efficient to conduct a 
conference between the physician and the correspond-
ing IBD clinic staff members, including the radiologist 
and pathologist, to discuss radiological imaging and 
pathology results. Thus, the organization can differ de-
pending on the situation. A multidisciplinary approach 
to cancer management with organizational support is 
usually applied in real-world clinical settings to improve 
the effectiveness of clinical decision-making. In Korea, 
the fee for multidisciplinary consultation has officially 
been covered by national insurance since 2014, although 
such coverage was applicable to only some cancer pa-
tients. However, since 2017, insurance coverage has ex-
panded to include other cancers, tuberculosis, and rare 
incurable diseases, including CD, UC, and intestinal 
bowel disease. Therefore, multidisciplinary consultation 
with such patients and their families can be performed 
systematically and officially in tertiary hospitals in Ko-
rea. A multidisciplinary approach is the most important 
feature of the IBD center. To optimize management and 
time efficiency, in cases involving colorectal cancer, it 
may make sense to conduct the patient consultation in 
parallel with the cancer multidisciplinary team, espe-
cially if the same members are involved in both teams.
Among the activities of IBD centers/clinics, in terms 
of patient care, the assessment of IBD severity is another 
key factor. The CD activity index [29,30], Mayo score [31], 
and disease activity index for intestinal bowel disease 
[32] are simple and adequate measures used for person-
alized risk stratification and should be adapted accord-
ing to the therapeutic plan. Radiological or endoscopic 
evaluation is also a tool for risk stratification. Further-
more, the use of tablets to create diaries and simultane-
ously share/archive these diaries in electronic medical 
records is also recommended. High-risk patient groups 
requiring special management, short bowel syndrome 
patients, and those likely requiring surgery or at high 
risk of infection can be easily referred to sub-clinics 
such as those specializing in transitional care, fertility, 
or ostomy, as mentioned earlier. In particular, patients 
treated with immunomodulators or biologics require 
considerably more monitoring. Drug trough levels, 
complete blood counts, signs or symptoms of infection, 
and infusion reactions should be monitored frequent-
ly. Therefore, special management of high-risk patient 
groups is required for these situations. Dietitians can 
play an important role within the multidisciplinary 
team by assessing nutritional status, measuring dietary 
intake, and suggesting tailored oral or parenteral nutri-
tional support in inpatients or outpatients. To increase 
patient adherence, the Severance Hospital IBD Clinic 
operates a follow-up telephone call system known as 
“Happy Call” for patients who miss outpatient clinic 
appointments and an additional telephone call service 
Table 2. Scope of the work conducted at the Severance Hospital IBD Clinic (Seoul, Korea)
Patient care Patient outreach System management
• Managing newly diagnosed patients
• Arrange patients’ schedule
• Assess the IBD severity
• Multidisciplinary conference
• Sub-clinic/part meeting
• Monitoring patients’ safety




• Managing local referrals 
• Happy call 
• Severance IBD seminar (annual)
• Small group lecture (bimonthly)
• Doctor’s Blog
• YouTube 
• IBD newsletter (quarterly)
• Educational materials in the outpatient 
clinic
• Emergency counselling 
 (e-mail, phone, SNS)
• Medical expenses support
• Discussing IBD clinic service
• IBD conference
• IBD journal review
• IBD clinical research/trials meeting
• Metrics management
IBD, inflammatory bowel disease; SNS, social network services.
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to provide pharmaceutical consultation for patients ex-
periencing difficulty taking, or adhering to, prescribed 
medications. Various other activities can be conducted 
under the umbrella of patient care, and these method-
ologies integrated within the scope of the IBD center/
clinic can improve approaches to standardizing patient 
management.
The patient outreach category is also based on col-
laboration among IBD center/clinic team members. 
IBD seminars, small group lectures, and other activities 
involving patient education or public relations should 
cover the diverse aspects of IBD treatment and the dis-
ease itself. Therefore, the assignment of activities is 
based on the needs and requirements of the IBD center/
clinic team. Because IBD occurs mainly in younger in-
dividuals and due to rapidly evolving information tech-
nologies, it may be better to conduct patient outreach 
activities via online communication, such as social net-
work services (SNS), rather than off-line lectures [33,34]. 
Moreover, the importance of electronic consultation via 
SNS or other internet platforms is even greater during 
the current coronavirus disease 2019 pandemic to en-
sure patient protection using the appropriate informa-
tion. A practical example is uploading lecture clips on 
YouTube (http://www.youtube.com) and posting infor-
mation sheets in online blogs. This may compensate for 
the lack of sufficient communication between doctors 
and patients in centers/clinics, playing a role in the dis-
semination of scientifically accurate information. IBD 
patients often experience emergency situations, such as 
acute abdominal pain, bleeding, and cramping, during 
which it can be difficult to decide whether to visit the 
emergency department [35]. For these situations, the 
Severance Hospital IBD Clinic provides medical staff 
contact information and emergency counseling via SNS 
as a patient outreach activity. 
Finally, the system management category is closely 
aligned with patient care and outreach. Clinical staff 
members work in close collaboration to ensure that all 
aspects of the IBD center meet the needs of the patients 
and the clinic itself, including strategic directions, fi-
nancial decisions, and educational and/or research pro-
grams. Thus, the typical IBD clinic conference addresses 
various issues pertaining to the continuous manage-
ment of clinics. Additionally, to provide scholarly up-to-
date education to IBD clinic staff members, residents, 
and fellows, conferences, journal reviews, and research 
meetings are conducted regularly as a component of the 
system management category
THE ROLE OF IBD NURSES
The most important resource for IBD clinic/center 
management is the IBD coordinator, more commonly 
known as the IBD nurse. Previous research has demon-
strated that IBD nurses can even influence patient qual-
ity of life. Most clinic/center activities are usually initi-
ated by IBD nurses, who are frequently affiliated with 
the department of gastroenterology because IBD patient 
care is generally provided by gastrointestinal physicians/
specialists. IBD nurses offer patients consistent support 
by arranging clinical appointments and providing edu-
cation, as well as organizing consultation schedules with 
other departments as needed. This is often described as 
a gatekeeper role, available under one roof—or “one 
time shopping”—at some hospitals. Therefore, IBD 
nurses must exhibit competence and expertise. Despite 
the need for professionalism, IBD nurses have access 
only to educational programs provided at the academ-
ic level (the Advanced Practice Provider Preceptor pro-
gram of the Crohn’s & Colitis Foundation [https://site.
crohnscolitisfoundation.org] and the European Crohn’s 
and Colitis Organisation IBD Nurse Education Program 
[https://ecco-ibd.eu/education/nurse-education-pro-
gramme.html]); however, there is no official or national 
certification program. Most of these nurses rely solely 
on educational programs provided by academic gastro-
enterology congresses or patient seminars. Moreover, 
the division of duties among IBD nurses is not always 
clear. In Korea, the Korea Nurses Association has the au-
thority to certify nurses and advanced practice nurses, 
but there is no certification available for gastrointestinal 
or IBD specialties. Generally, advanced practice nurses, 
registered nurses, and nurse practitioners in the gastro-
intestinal department play concurrent roles in IBD care. 
However, it is important to note that the certification 
and/or licensing of IBD nurses is anticipated to be for-
malized in the near future. 
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EFFECTIVE MANAGEMENT OF AN IBD CLINIC/
CENTER
IBD is a complex and systematic disease that often re-
quires multidisciplinary treatment. Therefore, an orga-
nized and controlled therapeutic approach is required 
[36]. Treatment schedules for IBD patients are generally 
managed by IBD nurses, who provide patients with con-
sistent support, arrange clinic appointments and edu-
cational opportunities, and plan consultation schedules 
with other departments, as needed [37]. However, for 
several hospitals overseeing multiple IBD patients, it 
may be difficult for a single IBD nurse to handle all of 
these aspects. Hence, it is more effective to establish an 
IBD clinic/center in hospitals where IBD patients have 
feasible contact with IBD clinicians. Hashash et al. [38] 
suggested eight steps for developing an IBD treatment 
program for hospitalized patients, including the ap-
pointment of leadership, establishing staff support, ar-
chiving educational materials, and developing a training 
manual for volunteers. To design such a clinic/center 
within a hospital, organizational support, including the 
provision of staff members, budget, and space, is essen-
tial and requires the cooperation of many other depart-
ments within the hospital. 
Adopting the systems of well-known IBD centers is 
not easy in general hospitals or in hospitals without 
available institutional support. Therefore, to improve 
the quality of care for IBD patients and effectively pro-
vide integrated treatment, efforts to organize these steps 
or integrate IBD clinic/center activities into the pro-
gram require internal rather than external infrastruc-
ture. It is important to have flexibility so that IBD care 
programs can be executed according to each hospital’s 
situation and/or capabilities. For example, some hospi-
tals can only run transition clinics based on coopera-
tion between the gastroenterology and pediatric depart-
ments, whereas others can only prepare patient survey 
systems and educational materials focusing on patient 
outreach. All activities can be gathered and distributed 
according to the situation, as mentioned in Table 2. The 
key factor is that the programs are focused on ensuring 
patient safety and convenience based on the integration 
of leading department physicians and IBD nurses. 
To develop a sustainable IBD patient care program, 
the following strategic elements should be considered: 
the number of patients; service staff sustainability and 
resiliency; scope of the activities, responsibilities of, and 
communication and coordination with staff members; 
clinical care space; and administrative processes [39]. 
Practically, the clinic’s own guidelines or standardized 
processes should be based on the consensus of all affil-
iated members. The simulation of program activities is 
an effective method for training team members in the 
management of any difficult situations and improving 
team performance in terms of communication, espe-
cially in resuscitation care or emergency situations [40]. 
The IBD clinic/center does not need to make decisions 
pertaining to patient care services. However, establish-
ing a procedural flow to alleviate trial-and-error scenar-
ios may be helpful. 
Finally, for effective management, several metrics for 
clinics/centers should be determined to assess the qual-
ity of the care service and patient satisfaction [41]. These 
metrics may include the number of multidisciplinary 
care teams, number of dedicated clinic members, num-
ber of patient lectures, patient participation rate in 
seminars/lectures, rate of follow-up loss, adverse event 
metrics, IBD clinical trial/research metrics, and patient 
satisfaction measures. Any set of metrics is permitted 
according to the scope of the IBD care program activi-
ties. The analysis of these metrics should highlight any 
weak aspect of clinical management and guide the next 
steps in the operation of the center. 
CONCLUSIONS
The prevalence and incidence rates of IBD in East Asian 
countries, including Korea, Taiwan, Japan, and China, 
have nearly reached those reported in Western coun-
tries. Accordingly, the number of clinical trials on, and 
level of physician interest in, the systematic care of IBD 
patients have increased and are expected to continue in 
the future. Most tertiary hospitals in Korea established 
IBD centers during the 2010s, and such centers are the 
most effective tools for resource integration. However, 
for greater flexibility, tailored programs should be es-
tablished, rather than following the structure of larger 
centers according to the competencies and size of each 
hospital. Short-term goals to integrate resources related 
to patient care, patient outreach, and system manage-
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ment should be set (Table 2). Furthermore, a long-term 
goal is to modify and develop previous settings to en-
sure the quality of expert-based standard care. Thus, 
IBD treatment and patient care do not always require 
the formal establishment of a center; however, they 
must be incorporated into the general setting of each 
hospital as an adaptable program that can be adjusted to 
meet a wide range of outcomes. 
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